6results about How to "Reduce inflammatory damage" patented technology

The invention particularly relates to a glycosylated dendrimer for co-delivery of small interfering RNA (Ribonucleic Acid) and small molecular drugs as well as a preparation method and application of the glycosylated dendrimer. The nano platform provided by the invention is characterized in that an anti-inflammatory drug resveratrol (Res) and electrostatic adsorption small interfering RNA (si-Cp2e1) are loaded in a glycosylated dendrimer G5-Gal. The preparation method and the application comprise the following steps: preparation of G5-Gal, preparation of Res (at) G5-Gal, and preparation of Res (at) G5-Gal / si-Cp2e1. The preparation method is simple, the required raw materials are easy to obtain, the synthesis process is simple and convenient, separation and purification are easy, and the synthesized nano-drug has a liver targeting capability, can realize dual treatment of small molecule drug-small interfering RNA, and has a potential application prospect in the aspect of treatment of alcohol-related liver diseases.

The application discloses a kind of nanocomposite hydrogel for treating osteoarthritis and its preparation method and application, the nanocomposite hydrogel includes cerium dioxide nanoparticles, the cerium dioxide nanoparticles are modified with hyaluronic acid;Ergothioneine is loaded on hyaluronic acid modified cerium dioxide nanoparticles to form nanocomposite EGT-CeO2@HA;And temperature-sensitive hydrogel carrier, the nanocomposite EGT-CeO2@HA is uniformly dispersed in the temperature-sensitive hydrogel carrier.This composite hydrogel can activate ATF4-dependent pro-survival autophagy pathway, reduce cartilage cell inflammatory damage, and improve cartilage degeneration.

The application of ursolic acid in the preparation of drugs for treating liver fibrosis can effectively solve the problem of medication for treating liver fibrosis. By regulating the differentiation of immune cells (Th17 cells) and reducing inflammatory damage, ursolic acid intervenes in the liver's immune microenvironment, effectively reversing liver fibrosis, and thus enabling its application in the preparation of drugs for treating liver fibrosis. This invention develops a new drug for treating liver fibrosis, opening up a new avenue for medication in the treatment of liver fibrosis. It represents a major innovation in the treatment of liver fibrosis, demonstrating good efficacy, safety, and practical application value.

The application discloses application of a pilose antler polysaccharide in preparation of a radioactive liver injury protection product and belongs to the technical field of biological pharmacy. The application of the pilose antler polysaccharide in preparation of the radioactive liver injury protection product shows that the polysaccharide can not only effectively reduce oxidative stress and inflammatory injury, but also specifically intervene in the core pathological mechanism of the radioactive liver injury, that is, the pilose antler polysaccharide can inhibit progressive liver fibrosis by down-regulating the expression of a TGF-beta signal path and regulate the expression balance of BAX / Bcl-2 genes to block liver cell apoptosis mediated by a mitochondrion path, thereby effectively relieving liver injury caused by ionizing radiation, and the pilose antler polysaccharide has no toxic side effects and has a wide application prospect.

This invention provides a 20(S)-ginsenoside Rg2 amino acid ester derivative, its preparation method, and its uses, belonging to the pharmaceutical field. This invention relates to its application in drugs for treating shock diseases. In vitro cell experiments show that the compound of this invention can not only improve the survival rate of hypoxic-damaged cardiomyocytes, inhibit the increase of LDH, MDA, TNF-α, and IL-6 levels in hypoxic-damaged cells, and increase SOD activity, but also promote the expression of p-PI3K and p-Akt in hypoxic-damaged cells, exhibiting a strong protective effect against hypoxic cardiomyocytes. This invention can also increase blood pressure in shock model rats, inhibit the increase of heart rate, reduce lactate content to improve tissue perfusion, and reduce PCO2 content while increasing HCO3 content. ‑ It reduced the levels of TCO2 and BE, corrected the acid-base balance in the body, significantly reduced the content of MDA, LDH, TNF-α and IL-6, increased the activity of SOD, inhibited oxidative stress and inflammatory response, and showed good anti-shock biological activity.

The invention discloses a moisturizing mask and a preparation method thereof, and relates to the technical field of masks, the mask comprises a mask matrix and essence; the essence is prepared from the following raw materials in parts by weight: 80-90 parts of water, 4-6 parts of butanediol, 1-3 parts of 1, 3-butanediol and 1-3 parts of 1, 3- The cosmetic is prepared from the following raw materials in parts by weight: 1 to 5 parts of 1, 3-propylene glycol, 1 to 2 parts of betaine, 0.5 to 1.5 parts of glycerol, 1 to 3 parts of glyceryl polyether-26, 0.1 to 1 part of p-hydroxyacetophenone, 0.1 to 0.5 part of saccharide isomeride, 0.1 to 0.5 part of carbomer sodium, 0.1 to 0.5 part of dendrobium huoshanense stem extract, 0.1 to 0.3 part of cottonrose hibiscus leaf extract, 0.1 to 0.3 part of tamarind seed fermentation extract, 0.01 to 0.05 part of sodium hyaluronate, 0.001 to 0.01 part of oligopeptide-1, 0.001 to 0.005 part of citric acid and 0.001 to 0.005 part of sodium citrate. And 0.0001 to 0.001 part of acetyl hexapeptide-8. The moisturizing performance of the mask is remarkably improved.